Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
ImmunoGenesis
With
Threshold Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects greater than or equal to (\>=) 18 years of age with locally advanced unresectable or metastatic pancreatic adenocarcinoma proven by histology or cytology and previously untreated with chemotherapy or systemic therapy other than:
* Radiosensitizing doses of 5-fluorouracil;
* Radiosensitizing doses of gemcitabine if relapse occurred at least 6 months after completion of gemcitabine;
* Neoadjuvant chemotherapy if relapse occurred at least 6 months after surgical resection;
* Adjuvant chemotherapy if relapse occurred at least 6 months after completion of adjuvant chemotherapy
Subjects may have measurable or non-measurable disease according to RECIST 1.1.
Eastern cooperative oncology group (ECOG) performance status of 0 or 1
Acceptable hematological status, liver and renal function as defined in the protocol
You may not be if
Significant cardiac or peripheral vascular arterial disease
Known brain, leptomeningeal or epidural metastases (unless treated and well controlled for at least 3 months)
Severe chronic obstructive or other pulmonary disease with hypoxemia
Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
Subjects receiving concomitant treatment with radiotherapy or other investigational drugs
Clareo Health | Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer
